| ADMA Biologics is a commercial biopharmaceutical company. Co.'s products include: BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI), also known as Primary Immunodeficiency Disease; ASCENIV (Immune Globulin Intravenous, Human – slra 10% Liquid), an IVIG product indicated for the treatment of PI; and Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. Co.'s products and product candidates are intended to be used by physician personnel. We show 33 historical shares outstanding datapoints in our ADMA shares outstanding history coverage, used to compute ADMA market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ADMA market cap history over the course of time is important for investors
interested in comparing ADMA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ADMA versus a peer is one thing; comparing
ADMA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ADMA can fluctuate over the course of history.
With this page we aim to empower investors researching ADMA by allowing them to research the ADMA market cap history.